Is there a drug for every disease?

Nominee for the European Inventor Award Category Research: Christine van Broeckhoven, Belgium, Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) for her invention: Contributions to neuropathological medicine (on the left). The European Inventor Award, launched by the EPO and EC's DG Enterprise and Industry in 2006, gives inventors the recognition they deserve. And, like every competition, it is an incentive to all other potential winners. It protects ideas and encourages innovation.

Nominee for the European Inventor Award Category Research: Christine van Broeckhoven, Belgium, Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) for her invention: Contributions to neuropathological medicine (on the left). The European Inventor Award, launched by the EPO and EC’s DG Enterprise and Industry in 2006, gives inventors the recognition they deserve.

Pharmaceutical firms in Europe have an awkward relation with their customers. The truth is that their selling prices and product licencing are directly or indirectly controlled by the buyers, that is governments, or government control health insurance schemes, offering almost free health services to citizens. As everybody knows governments are not only able to influence the approval of new drugs, they are also empowered with the ability to set prices by law.With healthcare costs skyrocketing over the past years and the fiscal crisis having engulfed almost all the 27 EU member states, governments have become very careful over their budgets and spending. In view of that, governments have at least two first hand possibilities, to cut down the drug bill.

For one thing officials can reject the use of new and expensive drugs on the grounds that they have no additional cure properties compared to existing formulas or generic medicines. Secondly, governments can set prices by law, or ask the pharmaceutical firms to return a part of their proceeds at the end of the year. As for the licencing procedure it is a common secret that it can be influenced by state officials.

In view of all that pharmaceutical companies are obliged on many occasions to retreat some of their drugs from entire countries, if the governments are not willing to pay what the firms demand. Another dreadful development is that the arbitrary settings of drug cost by governments, leads some times to huge price differences of the same drug, even in neighbouring countries. In this way large incentives for parallel exports are created, to the detriment of the maker.

Greece is an example of all that absurdities in the market of drags.

Greece

This debt stricken and practically bankrupt country has a history of high drug bills. Government spending on medicines skyrocketed within a few years, from 2002 to 2008. In this short time interval, state budget and public health schemes spending on medicines, doubled to €9 billion from less than €5bn. This outrageous development was the outcome of fraudulent behaviour all along the line. Doctors issued hideously expensive prescriptions, patients didn’t mind because they didn’t pay themselves and pharmacists had a guaranteed 30% profit on sales. During the same time period the number of pharmacies almost doubled and today their numbers per 100,000 of population are 60% above Belgium, the country with more pharmacies in the European Union.

As everybody remembers however, towards the end of 2009 Greece found difficulties in honouring its public debt and within months Eurozone had to support Athens, in order this Eurozone country to avoid bankruptcy. From then onwards Greece is under strong pressure to cut down government spending. To a large extend those fiscal deficit reductions are realised through deep cuts on public bills on drugs. Actually the Greek government doesn’t pay at all its drag bills for many months in a row, posing grave liquidity problems to makers, wholesalers and pharmacists.

The Greek authorities however are using more “methods” to cut down the drag bill. Successive Health Ministers had a rough time, trying to expand the use of generics. Expenditure on prototypes was 80% of total, while in Swiss home to many pharmaceutical giants, such generosity is out of question. In any case medicines are not the only bitter pills, Greece should take. A major reorganisation of the country’s health system was long overdue, but the government rushed to economise on the easy target, which is the expenditure on medicines.

Due to continued government inability to tackle the problem in a rational and organised way over the past months, the entire public health system of Greece is in a desperate state, with everybody going on strike and first degree health care and hospitals deep in the red.

Incidentally the abuse of prototype drags is responsible for only a small part of the huge debts the Greek health system accumulates every month. The Greek government owes billions of euros to many Pharmaceutical firms and some of them are threatening to abandon the country altogether and retreat their drags. Unfortunately there is no end to what is wrong with the Greek health system.

Mismanagement and corruption reigned for decades in public hospitals and the first degree health care system of the country, starting from the unholy alliance of doctors and pharmacists, to the exploitation of hospital patients by doctors. It is not clear which direction the whole issue will take, but it is more that certain a lot of things are to change. Probably the public healthcare system will shrink and the private sector will take its place.

But let Greece cure its own diseases and direct this discussion to the powerhouse of pharmaceutical industry, the R&D.

New drags

No need to say, that success in this department is key to survival and growth. Understandably, pharmaceutical firms can secure additional receipts and extra profits only from new drugs, the development and licencing of which though is becoming all the time more complicated and expensive. On top of that research and development of new formulas has become so focused and specialised, that on many occasions it is carried through more successfully by small groups or even one scientist in private laboratories or universities.

As a result major companies with big, expensive and sometimes rigid R&D departments cannot compete with independent researchers. Practice has shown that the solution the large multinationals now prefer is to buy out small research firms rather than develop new drags by themselves. Still however there are great risks and large investments are required.

“To help cope with declining revenue, Pfizer, Eli Lilly & Co., Bristol-Myers and AstraZeneca will probably increase spending on acquisitions beyond their normal budgets because of “deep operating challenges coupled with deep pockets,” Fitch Ratings said last week”, and Bloomberg reported.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

UN agencies launch emergency plan for millions of Venezuelan refugees and migrants

“TTIP can boost the European project”; the Sting reports live from EBS 2015 on TTIP

Who would pay and who is to gain from the EU-US free trade agreement

Mine ban agreement ‘has saved countless lives’, but ‘accelerated efforts’ needed to end scourge for good: Guterres

Quashing myths on 2019-nCoV for better public management

Why trade wars have no winners

Women in Switzerland have gone on strike – this is why

Act now to prevent Desert Locust catastrophe in Horn of Africa: UN agencies

Can climate change wait for the US to rejoin the Paris agreement?

High internet taxes are restricting access and slowing economic growth

‘Real change’ involving women in peace and security, still too slow, Guterres tells Security Council

SRHR and ending HIV: Can one be achieved without the other?

Paris agreed with Berlin over a loose and ineffective banking union

How we can survive the great COVID lockdown: IMF Chief Economist Gita Gopinath

Seaweed, enzymes and compostable cups: Can ‘Big Food’ take on plastic and win?

Making Artificial Intelligence ethical, safe and innovative

State aid: Commission invites comments on simplified rules for State aid combined with EU support

Convincing the Germans to pay also for the unification of Eurozone

5 ways to go green in your own kitchen

No tears for Cyprus in Brussels and Moscow

Secretary-General calls for global participation in UN75 dialogues for better future for all

Parliament approves key directive regulating professional qualifications

EU confronts environmental threats as global leaders attempt to revive the global sentiment at NYC climate week

Google’s hot summer never ends: EC to launch ANOTHER antitrust inquiry against the American giant

Iran: BBC and other broadcast journalists harassed; families threatened – UN experts

Pharmaceuticals spend millions to push TTIP while consumer groups spend peanuts

EU Budget 2019: focus on the young, on migration and innovation

Health spending set to outpace GDP growth to 2030

Fossil fuel support is rising again in a threat to climate change efforts

Coronavirus: Commission starts testing interoperability gateway service for national contact tracing and warning apps

Here’s how the EU is doing on gender equality

How a different kind of investment could transform Latin America

The price of centralization of human resources for health

In the United States, there aren’t enough hours in the week to make rent

EU to give more power to national antitrust authorities in a bid to secure regulatory fines

Two days left until General Data Protection Regulation (GDPR), lots of newsletter opt-outs but does the EU citizen really know?

What are Asia Pacific countries getting right in the fight against cancer?

MEPs call for EU rules to better protect minorities’ rights

EP leaders call for negotiations on upgraded Transparency Register to continue

Boeing subsidy case: World Trade Organization confirms EU right to retaliate against $4 billion of U.S. imports

EU-US Privacy Shield data exchange deal: US must comply by 1 September, say MEPs

Is the European Banking Union an impossible task?

Balancing The Broken See-Saw of Gender Power Dynamics as a Medical Student

The middle-class dream is moving beyond millennial reach

The benefits of a cashless society

EU approves disbursement of €500 million in Macro-Financial Assistance to Ukraine

Sudan: top UN official demands cessation of violence and rape against civilians by security forces

Timor-Leste Foreign Minister highlights value of UN in resolving conflicts

Global Citizen – Volunteer Internships

Fighting Depression In the Isolation of COVID-19

Charges against Baha’i in Yemen must be dropped: UN experts urge release of detainees

Syria: A bloody tracer of Trump – Putin rapprochement

What is true and not true about the new Coronavirus?

Scientists in Iceland are turning carbon dioxide into rock

Be a part of the World Forum on Future Trends in Defence and Security

Hiring more female leaders is good for profits. Here’s the evidence

Lithuania vs Parliament over 2014 EU budget

EU’s guidelines on net neutrality see the light although grey areas do remain

‘A new chapter’ dawns for democracy in Guinea-Bissau: top UN official

6 ways social innovators are harnessing 4IR technologies for social change

More Stings?

Advertising

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s